Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | RBP4 | P02753 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19925766 | 0.85 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL2334032 | 0.85 | STS (0.48) | — | |
| SCHEMBL28059306 | 0.81 | HCRTR2 (0.36) | MEN1KMT2ARBP4SLC6A2SLC6A4 | |
| SCHEMBL2099816 | 0.78 | RBP4 (0.47) | MEN1KMT2ARBP4 | |
| SCHEMBL19212250 | 0.76 | GRM5 (0.44) | MEN1KMT2ATACR1CHRM1 | |
| SCHEMBL22524566 | 0.76 | STS (0.49) | — | |
| SCHEMBL4680013 | 0.76 | RBP4 (0.45) | MEN1KMT2ARBP4 | |
| SCHEMBL14813739 | 0.75 | PTGDR2 (0.47) | MEN1KMT2ARBP4SLC6A2SLC6A4 | |
| SCHEMBL1662407 | 0.75 | MEN1 (0.46) | MEN1KMT2ARBP4CHRM4CHRM1 | |
| SCHEMBL1558279 | 0.75 | HTR1A (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3506900-A1 | COMPOUND FOR USE IN THE TREATMENT OF NEUROGENIC ORTHOSTATIC HYPOTENSION | Theravance Biopharma R&D IP, LLC (US) | 2019-07-10 | — | — | EP | disclosed |
| WO-2018044667-A1 | COMPOUND FOR USE IN THE TREATMENT OF NEUROGENIC ORTHOSTATIC HYPOTENSION | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-03-08 | — | — | WO | disclosed |
| EP-2358675-B1 | 4-[2-(2-Fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE INC (US) | 2012-10-03 | — | — | EP | disclosed |
| EP-2358676-A1 | Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound | Theravance, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| EP-2358674-A1 | Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl¨]iperidine compounds | Theravance, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010056939-A1 | CRYSTALLINE FORM OF A 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUND | THERAVANCE, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056938-A1 | PROCESS FOR PREPARING 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2010-05-20 | — | — | WO | disclosed |